Long-term antiplatelet monotherapy after PCI: searching for the smart choice.
作者信息
Gragnano Felice, De Sio Vincenzo, Galli Mattia, Calabrò Paolo
机构信息
Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Viale Abramo Lincoln 5, Caserta IT-81100, Italy.
Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano', Caserta, Italy.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):322. doi: 10.1093/ehjcvp/pvaf032.
Abstract
摘要
相似文献
1
Long-term antiplatelet monotherapy after PCI: searching for the smart choice.PCI术后的长期抗血小板单药治疗：寻找明智之选。
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):322. doi: 10.1093/ehjcvp/pvaf032.
2
P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.短期双联抗血小板治疗后 P2Y12 抑制剂单药治疗与阿司匹林单药治疗用于经皮冠状动脉介入治疗：来自随机试验网络荟萃分析的见解。
Am Heart J. 2020 Sep;227:82-90. doi: 10.1016/j.ahj.2020.06.008. Epub 2020 Jun 15.
3
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.经皮冠状动脉介入治疗后 P2Y12 抑制剂单药治疗的长期影响：SMART-CHOICE 随机临床试验 3 年随访结果。
JAMA Cardiol. 2022 Nov 1;7(11):1100-1108. doi: 10.1001/jamacardio.2022.3203.
4
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.P2Y12 抑制剂单药治疗与急性冠状动脉综合征中常规双联抗血小板治疗或阿司匹林单药治疗的比较：SMART-DATE 和 SMART-CHOICE 试验的汇总分析。
Am J Cardiol. 2021 Jul 1;150:47-54. doi: 10.1016/j.amjcard.2021.03.053. Epub 2021 May 16.
5
Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.比较经皮冠状动脉介入治疗的糖尿病患者和非糖尿病患者中 P2Y12 抑制剂单药治疗与双联抗血小板治疗的疗效和安全性。
Int J Mol Sci. 2022 Apr 20;23(9):4549. doi: 10.3390/ijms23094549.
6
The impact of body mass index on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A substudy of the HOST-EXAM trial.
Am Heart J. 2025 Dec;290:258-267. doi: 10.1016/j.ahj.2025.07.005. Epub 2025 Jul 5.
7
Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials.短期双联抗血小板治疗后优选单药治疗：随机试验的系统评价和网络荟萃分析。
J Cardiol. 2024 May;83(5):338-347. doi: 10.1016/j.jjcc.2023.08.001. Epub 2023 Aug 9.
8
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.氯吡格雷与阿司匹林单药治疗对经皮冠状动脉介入治疗后发生后续心血管事件高危患者的疗效和安全性（SMART-CHOICE 3）：一项随机、开放标签、多中心试验
Lancet. 2025 Apr 12;405(10486):1252-1263. doi: 10.1016/S0140-6736(25)00449-0. Epub 2025 Mar 30.
9
Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis.缺血性中风或短暂性脑缺血发作后的长期抗血小板单药治疗和双联治疗：网状Meta分析
J Am Heart Assoc. 2015 Aug 24;4(8):e002259. doi: 10.1161/JAHA.115.002259.
10
P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-Term Secondary Prevention Post-PCI.P2Y12抑制剂单药治疗：PCI术后急性和长期二级预防的考量
Rev Cardiovasc Med. 2022 Oct 17;23(10):348. doi: 10.31083/j.rcm2310348. eCollection 2022 Oct.
本文引用的文献
1
Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.氯吡格雷与阿司匹林单药治疗对经皮冠状动脉介入治疗后发生后续心血管事件高危患者的疗效和安全性（SMART-CHOICE 3）：一项随机、开放标签、多中心试验
Lancet. 2025 Apr 12;405(10486):1252-1263. doi: 10.1016/S0140-6736(25)00449-0. Epub 2025 Mar 30.
2
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.先天性出血性疾病患者的管理以及抗血栓治疗的心脏适应症
Eur Heart J Cardiovasc Pharmacother. 2025 May 2;11(3):275-289. doi: 10.1093/ehjcvp/pvaf006.
3
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.国际经皮冠状动脉介入治疗血小板功能与基因检测共识声明：2024 更新版。
JACC Cardiovasc Interv. 2024 Nov 25;17(22):2639-2663. doi: 10.1016/j.jcin.2024.08.027.
4
Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention.用于预测经皮冠状动脉介入治疗后出血的PRECISE-HBR评分的推导与验证。
Circulation. 2025 Feb 11;151(6):343-355. doi: 10.1161/CIRCULATIONAHA.124.072009. Epub 2024 Oct 27.
5
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis.急性冠状动脉综合征中短期 DAPT 后 P2Y12 抑制剂单药治疗：系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):588-598. doi: 10.1093/ehjcvp/pvae057.
6
P2Y Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.P2Y 抑制剂或阿司匹林单药治疗用于冠心病事件的二级预防。
J Am Coll Cardiol. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051.
Zotero 插件